Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, November 4, 2026

Back to the front page

The Buyback Shows Up (ESRT Q3 2026)

Empire State Realty Trust repurchased $85.8 million of shares at $4.56 each, using 1359 Broadway sale proceeds to fund buybacks and debt reduction.

ESRT $1.3B
Orphan REITs 6 clicks

From X

@kevin__mak

Kevin Mak on X

$CMPS Lots to be excited about for the company and the space. Specifically there's been a lot of "thematic" interest in the psychedelics/psilocybin space in the last few weeks, and I expect that to continue. The most notable event recently is an article published in the New England Journal of Medicine: "FDA's New Framework for Psychedelic Drugs" (paywall) https://t.co/rdkgp5GsOG This was co-authored by Michael Davis (just named permanent director of CDER) and the FDA's top psychiatry and neuroscience reviewers. They're the group that ultimately approves/rejects COMP360 (and other psychedelic drugs). Aside from approve/reject, they will be helping negotiate/decide the "label" and essentially how permissive or strict the availability of these drugs/therapies are. The devil is in the details and hearing the FDA publicly state that they are aligned, i.e. "let's make sure these drugs get to market safely AND effectively" versus "this is weird/different, lets be extra cautious/slow with the roll out" is very important to both shareholders, and patients who could potentially be helped by these therapies. Another interesting article is here: WSJ: "Elon Musk's Inner Circle is Pouring Cash Into Making Psychedelics Mainstream" https://t.co/pfuE6JqBGD It is widely expected that COMP360 from $CMPS is going to be the first classic psychedelic (Psilocybin) drug to be approved and commercially available. Despite this being "priced in" by people who follow markets (or the industry) closely, I believe there's a good chance there's a positive public reaction to the headline when/if it comes out in the coming months. More importantly, I think we're at the very early innings of a treatment category that will be highly beneficial to a group of patients who historically have not had great treatment options. My full write on $CMPS is below, I have a $45 price target: https://t.co/rVZOU3yIz6 Disclosure: Creek Drive and its affiliated funds does hold a long position in CMPS. Views expressed are current opinions for informational educational only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in bio for more important information.

Investor Letters

All letters

New Ideas From The Road

Aurelion Research increased healthcare exposure and sees opportunities in banking and defense, alongside research on Alcoa, Nike, ONON and…

AA $10BNKE $60B
Aurelion Research 4 clicks

Site Centers (NYSE:SITC)

Site Centers' $3 per-share return-of-capital distribution and December delisting leave a discounted liquidation stub, with two properties…

CURB $3.6B
Real Assets, Real Value 5 clicks

Coupang: 3Q26 Business Recap

Coupang’s product-commerce growth rose 9% as data-leak effects fade, while management expects margins to return to pre-incident levels by…

CPNG $27B
Speedwell Memos 3 clicks

update on Gartner

Gartner’s growth has stalled after federal contract losses and cautious commercial spending, raising questions about its competitive…

IT $13B
scuttleblurb 1 click

Recycle Bin

Used aircraft engines can be repurposed as gas turbines, easing data center power constraints while tightening aviation supply.

EQT $33BRRC $12B
Doomberg 8 clicks
AMRZ · long

Amrize

Amrize (AMRZ) produces aggregates, cement and roofing materials across the US and Canada.

AMRZ $22B
Value Investors Club 3 clicks

TWLO Q3 FY12/26 Earnings Review

Twilio's Q3 revenue rose 20% to $1.56 billion, but Q4 organic growth guidance fell to 11% to 12% and RPO declined 28%.

TWLO $33B
Cestrian Capital Research 3 clicks

Stevanato down 30%. Yikes.

Stevanato fell 30% after forecasting low-single-digit 2027 growth as lower Nexa syringe volumes from a GLP-1 customer offset solid Q3…

STVN $3.6B
Best Anchor Stocks 3 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 75 of 279

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.